- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
D. Kyle Sampson
News 3 results
In the News · Source: PharmaCircle
October 21, 2025
Kyle Sampson comments on FDA drug approvals slowing down as a result of budget cuts and the government shutdown
In the News · Source: Bloomberg Law
Press Release
April 1, 2016
King & Spalding Boosts FDA & Life Sciences Practice with Addition of Three-Lawyer Team in Washington, D.C.
Events 13 results
Webinar
May 20, 2026
Clinical Trials Under the Microscope: Navigating FDA’s New Rules and DOJ Enforcement
Conference
April 8, 2026
Annual California Life Sciences Summit
Conference
November 4, 2025
King & Spalding Pharmaceutical University 2025
Conference
September 4, 2025
18th Annual King & Spalding Medical Device Summit
Insights 29 results
Client Alert
May 12, 2026
FDA’s New Oversight Tool: One-Day Inspectional Assessments
Client Alert
April 20, 2026
FDA Reminds Sponsors and Researchers to Disclose Clinical Trial Results to ClinicalTrials.gov
Client Alert
March 10, 2026
FDA Issues Draft Guidance on Responding to FDA Form 483 Observations Following Drug Inspections
Client Alert
February 16, 2026
FDA Issues Refuse-to-File Letter for mRNA-based Vaccine BLA